Herbal medicines for metabolic diseases with blood stasis A protocol for a systematic review and meta-analysis

被引:4
作者
Ko, Mi Mi [1 ]
Jang, Soobin [1 ]
Jung, Jeeyoun [1 ]
机构
[1] Korea Inst Oriental Med, Clin Med Div, Daejeon 305811, South Korea
关键词
blood stasis; herbal medicine; Metabolic disease; systematic review;
D O I
10.1097/MD.0000000000014543
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Herbal medicines have the potential to be alternative treatments for metabolic diseases. This systematic review will assess the efficacy of herbal medicines in treating metabolic diseases with blood stasis. Methods and analysis: We will search MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, 2 Korean medical databases (OASIS, NDSL), a Chinese database (China National Knowledge Infrastructure, CNKI), and a Japanese database (J-STAGE) for relevant literature. We will include all randomized controlled trials (RCTs) or quasi-RCTs evaluating the effectiveness of herbal medicine. Participants of both sexes and of any age with clinically diagnosed metabolic disease with blood stasis will be included. Primary outcomes will include Blood-stasis syndrome score, TC, TG, HDL-C and LDL-C. Secondary outcomes will Blood pressure, FBS. ECG, prevalence rate of heart disease, and response rate. The risk of bias will be assessed using the Cochrane tool for assessing risk of bias. Discussion: The findings of this study will provide a summary of the current state of evidence regarding the effectiveness of types of herbal medicine in managing metabolic disease with blood stasis. In addition, this review will be expected to provide a base for clinical trials to confirm the efficacy of herbal medicine for treatments of metabolic disease with blood stasis.
引用
收藏
页数:3
相关论文
共 21 条
[1]  
[Anonymous], 2015, COMMERCIALIZATION PR, V27, P2
[2]  
[Anonymous], 2006, The IDF Consensus Worldwide Definition of the Metabolic Syndrome
[3]   Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome [J].
Carr, DB ;
Utzschneider, KM ;
Hull, RL ;
Kodama, K ;
Retzlaff, BM ;
Brunzell, JD ;
Shofer, JB ;
Fish, BE ;
Knopp, RH ;
Kahn, SE .
DIABETES, 2004, 53 (08) :2087-2094
[4]  
Cham Stephanie, 2016, Drug Saf Case Rep, V3, P1
[5]   Blood Stasis Syndrome and Its Treatment with Activating Blood Circulation to Remove Blood Stasis Therapy [J].
Chen Ke-ji .
CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2012, 18 (12) :891-896
[6]   The Metabolic Syndrome [J].
Cornier, Marc-Andre ;
Dabelea, Dana ;
Hernandez, Teri L. ;
Lindstrom, Rachel C. ;
Steig, Amy J. ;
Stob, Nicole R. ;
Van Pelt, Rachael E. ;
Wang, Hong ;
Eckel, Robert H. .
ENDOCRINE REVIEWS, 2008, 29 (07) :777-822
[7]  
Davies Jonathan T, 2016, Lipid Insights, V9, P13
[8]   HYPERINSULINEMIA - THE KEY FEATURE OF A CARDIOVASCULAR AND METABOLIC SYNDROME [J].
FERRANNINI, E ;
HAFFNER, SM ;
MITCHELL, BD ;
STERN, MP .
DIABETOLOGIA, 1991, 34 (06) :416-422
[9]   Effects of three different formulae of Gamisoyosan on lipid accumulation induced by oleic acid in HepG2 cells [J].
Go, Hiroe ;
Ryuk, Jin Ah ;
Hwang, Joo Tae ;
Ko, Byoung Seob .
INTEGRATIVE MEDICINE RESEARCH, 2017, 6 (04) :395-403
[10]   Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [J].
Grundy, SM ;
Cleeman, JI ;
Daniels, SR ;
Donato, KA ;
Eckel, RH ;
Franklin, BA ;
Gordon, DJ ;
Krauss, RM ;
Savage, PJ ;
Smith, SC ;
Spertus, JA ;
Costa, F .
CIRCULATION, 2005, 112 (17) :2735-2752